The Mark H Zangmeister Center

Summary

The Mark H Zangmeister Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Cancer and other specialties. The Mark H Zangmeister Center is involved with conducting 275 clinical trials across 385 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Jeanna L Knoble, Emily Whitman, and Sameh Mikhail, MD.

Top PIs

Clinical Trials running at The Mark H Zangmeister Center

Breast Cancer

Lung Cancer

Cancer

Bladder Cancer

Ovarian Cancer

Melanoma

Colorectal Cancer

Bladder Carcinoma

Pancreatic Cancer

Breast cancer

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria